Other substances

DREP-Secto

A candidate COVID-19 DNA-based vaccine.

Phase of research

Potential treatment - pre-clinical evidence

How it helps

Vaccine

Drug status

Experimental

1
 Supporting references
0
 Contradictory references
0
 AI-suggested references
0
 Clinical trials

General information

DREP-Secto is a candidate DNA-launched self-amplifying replicon RNA vector vaccine based on Semliki Forest virus genome. It encodes viral RNA replicase and an antigen (SARS-CoV-2 Wuhan-Hu-1 strain Spike ectodomain trimer stabilized in prefusion conformation) but lacks the genes for structural proteins. The vaccines self-amplifying activity results in adjuvant properties (Szurgot et al., 2021).

 

Supporting references

Link Tested on Impact factor Notes Publication date
DNA-launched RNA replicon vaccines induce potent anti-SARS-CoV-2 immune responses in mice
Spike protein DNA Animal model In vitro 		in vitro binding assay; HEK293T cells; HEK293T-ACE2 cells; C57BL/6J mice 4.00

Immunization in mice elicited anti-SARS-CoV-2 IgG (Th1 biased), neutralizing antibody, and T cell responses. The immunogenic response was weaker compared to DREP-S, unless it was further boosted with heterologous Spike protein immunization. The murine antibodies neutralized SARS-CoV-2 pseudotyped virus in vitro.

 Feb/04/2021
Export (.csv)